Drug Trial Radar · NCT00216840
Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Gel in Scalp Psoriasis
Last checked: Nov 19, 2026Latest source record: Feb 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,350
Actual
Start
Dec 2004
Primary completion
Not stated
Study completion Sep 2005
Sponsor
- Lead sponsor
- LEO PharmaIndustry
- Sponsor type
- Industry
- First posted
- Sep 22, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to evaluate whether once daily topical treatment for up to 8 weeks of calcipotriol 50 mcg/g plus betamethasone 0.5 mg/g (as dipropionate) gel is safe and more effective than betamethasone 0.5 mg/g (as dipropionate) in the gel vehicle and calcipotriol 50 mcg/g in the gel vehicle in patients with scalp psoriasis. The primary response criterion is the number of patients with absence of disease and very mild disease after 8 weeks of treatment.
Conditions
- Psoriasis of Scalp
Interventions
Calcipotriol plus betamethasone dipropionate (LEO80185 gel)Drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- - Patients with "Controlled disease" ("Absence of disease" or "Very mild disease") according to investigator's global assessment of disease severity at week 8.
Locations
7 sites in 7 countries. Site status is shown where the registry gives one.
Universitair Ziekenhuis Sint Rafaël, Dienst Dermatologie
Leuven, Belgium
Innovaderm Research Inc.
Montreal, Quebec, Canada
Policlinic of Dermatology, Medical Reception Centre
Turku, Finland
Hôpital Trousseau, Service de Dermatologie CHU Tours
Tours, France
Georg-August-Universität Göttingen, Abteilung Dermatologie und Venerologie
Göttingen, Germany
Universitair Medisch, Centrum St. Radboud, Afdeling Dermatologie
Nijmegen, Netherlands
Royal Gwent Hospital, Department of Dermatology
Newport, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.